Absci Corp (ABSI) company profile
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
About Absci
Services-Commercial Physical & Biological Research, SIC 8731
Absci Corporation is a clinical-stage biopharmaceutical company that designs and develops differentiated antibody therapeutics using an artificial intelligence platform integrated with laboratory testing. Its operations include an internal pipeline of drug candidates as well as partnered discovery programs. The company’s lead investigational therapeutic, ABS-201, targets prolactin receptor signaling to treat androgenetic alopecia and endometriosis. Absci also develops additional antibody programs, such as ABS-101, alongside early-stage oncology and immunology candidates. The firm collaborates with external pharmaceutical and biotechnology companies, offering AI-guided antibody discovery, de novo protein design, and lead optimization services to support partners' development pipelines.
The company conducts operations utilizing a combined wet-laboratory and dry-laboratory facility that spans more than 77,000 square feet. Its clinical development activities include multi-site clinical trials in Australia for its lead therapeutic candidate, while its business partnerships involve multinational pharmaceutical enterprises. The provided text does not state the location of the company's corporate headquarters.
Summary of the business section of Absci's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Absci Corp
- Headquarters
- Vancouver, WA
- Address
- 18105 Se Mill Plain Blvd 98683
- Phone
- (360) 949-1041
- Website
- absci.com
- Employees
- 140, Dec 31, 2025
- Industry
- Services-Commercial Physical & Biological Research
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Jose, California
Stock & identifiers
- Ticker
- ABSI
- Exchange
- Nasdaq
- IPO date
- Jul 23, 2021
- Shares outstanding
- 172M, Jul 31, 2026
- Public float
- $303.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1672688
- CUSIP
- 00091E109
- ISIN
- US00091E1091
- FIGI
- BBG011N54CJ8
- Share class FIGI
- BBG011N54DC3
- EIN
- 85-3383487
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sean McClain | Chief Executive Officer, Director | 10,822,389 |
| Todd Bedrick | SVP, CAO | 199,128 |
| Zachariah Jonasson | CFO / CBO | 484,918 |
| Ransi Mudalinayake Somaratne | CMO, Head of R&D | – |
| Andreas Busch | Chief Innovation Officer | 421,446 |
| Shelby J. Walker | Chief Legal Officer | 139,775 |
| Mary T. Szela | Director | 21,300 |
| Karen K. McGinnis | Director | 48,420 |
| Menelas N. Pangalos | Director | 242,408 |
| Daniel A. Rabinovitsj | Director | 33,420 |
| Joseph Sirosh | Director | 33,420 |
| Houten Frans Van | Director | 73,420 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Sean McClain President, Founder and Chief Executive Officer | $689.94K | $650.48K | $1.96M | $372.57K | $14.00K | $3.69M | -62% |
| Zachariah Jonasson, Ph.D. Chief Financial Officer and Chief Business Officer | $553.45K | $650.48K | $839.80K | $249.05K | $14.00K | $2.31M | -19% |
| Andreas Busch, Ph.D. Chief Innovation Officer* | $712.80K | $81.05K | $239.42K | $384.91K | $142.95K | $1.56M | -41% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 23, 2021
- Offer price
- $16.00
- Securities offered
- 12,500,000
- Gross proceeds
- $200.00M
- Exchange
- Nasdaq
- First trading day
- Jul 22, 2021
- First-day close
- $21.59+34.9%
- Lock-up ends (est.)
- Jan 18, 2022
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 140 employees, many of whom have advanced post-graduate degrees, primarily engaged in research and development and general and administrative functions.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 23, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 21, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 19, 2019 | Name change | Name changed from AbSci, LLC to Absci Corp |
See a number that looks wrong?